FORM 4 [ X ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may...
Notice of Preliminary Results THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED UNDER THE MARKET...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM...
LONDON, April 18, 2019 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (AIM: MPH), a clinical stage, UK-based...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C...
Table of Contents UNITED STATES SECURITIES AND...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule...
Filed by Mereo BioPharma Group plc pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: OncoMed...
REDWOOD CITY, Calif., March 15, 2019 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (“OncoMed”...
Filed by Mereo BioPharma Group plc pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company:...
This regulatory filing was too large to post into our database. Please use the link below to view the original filing on the Securities and...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.